Skip to content

The effect of pregabalin on obsessive symptoms in bipolar patients

Pregabalin as an adjunct to asual treatment for obsessive compulsive symptoms in bipolar disorder:a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251110067944N1
Enrollment
70
Registered
2025-12-01
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bipolar disorder with ocd. Bipolar disorder

Interventions

Intervention 1: Intervention group:Bipolar patients with comorbid obsessive-compulsive disorder are under mood stabilizer treatment, who are not in the acute phase of mood at the beginning of the stud

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Outpatients aged 18 to 60 years with a final diagnosis of bipolar disorder with obsessive-compulsive disorder receiving mood stabilizer or antipsychotic treatment who have taken an SSRI trial for at least 12 weeks and have not responded to treatment People with a Yale-Brown test score above 15 Individuals who have the patient's or guardian's consent to participate in a research project

Exclusion criteria

Exclusion criteria: Presence of a comorbid psychiatric disorder (schizophrenia, post-traumatic stress disorder, depression, eating disorder) Drug or alcohol use in the past 12 months based on history as well as positive drug test at baseline Taking drugs from the pregabalin family such as gabapentin, tiagabine, and topiramate Patient with mental retardation or other neurological cognitive disorders such as dementia, delirium, head trauma, seizures, apnea, obstructive sleep apnea Received ECT in the past 6 months If serious complications occur, the patient will be excluded from the study. Hypersensitivity to pregabalin or any of the ingredients in the placebo Pregnant and lactating women If the patient has a good response to conventional treatments, he/she will not be included in the study In case of impaired kidney function and increased creatinine, the trial should be discontinued

Design outcomes

Primary

MeasureTime frame
?Obsessive-compulsive symptoms?. Timepoint: Weeks 2, 4, 8, and 12?. Method of measurement: ?Yale-Brown Obsessive Compulsive Scale?.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactshahin norozi

Ahvaz University of Medical Sciences

norouzi-s@ajums.ac.ir+98 61 3320 4637

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026